(Nasdaq: MODD) Profile
OUR NEW PROFILE IS: (NASDAQ: MODD) MODULAR MEDICAL ANNOUNCES COLLABORATION WITH GLOOKO THERE ARE 1.9 MILLION INDIVIDUALS WITH TYPE 1 DIABETES IN THE US. 100% OF PATIENT POPULATION REQUIRE DAILY INSULIN INJECTION. ONLY 1 OUT OF 3 CURRENTLY USE AN INSULIN PUMP WE HAVE SEEN INSIDERT PURCHASE OVER 575K SHARES IN THE PAST 12 MONTHS WITH ZERO SALES ACCORDING […]
(Nasdaq: LQR) Profile
OUR NEW PROFILE IS: (NASDAQ: LQR) LQR HOUSE REPORTS 458% YOY REVENUE SURGE IN DECEMBER 2023, FUELED BY HOLIDAY ECOMMERCE SUCCESS LQR ANNOUNCES THE REPURCHASE OF 703,798 OF ITS SHARES, REPRESENTING 15% OF ITS TOTAL OUTSTANDING LQR IMPLEMENTED A 1-FOR-60 REVERSE STOCK SPLIT BACK ON NOVEMBER 30, DRASTICALLY REDUCING THE FLOAT INDEX INVESTMENT GROUP ACQUIRES […]
(Nasdaq: COCH) Profile
AS OF SEPTEMBER 30, 2023 THE COMPANY HAD $7.4 MILLION IN AVAILABLE CASH; TOTAL CASH INCLUDING RESTRICTED FUNDS WAS $16.8 MILLION ENVOY MEDICAL BECAME A NASDAQ LISTED COMPANY THROUGH A MERGER WITH ANZU SPECIAL ACQUISITION CORP I, WHICH CLOSED ON SEPTEMBER 29, 2023 THE JOURNAL OF CLINICAL MEDICINE HIGHLIGHTED EARLY SURGICAL EXPERIENCE WITH THE INVESTIGATIONAL ACCLAIM® FULLY IMPLANTABLE COCHLEAR IMPLANT. ACCORDING TO THE […]
(Nasdaq: MYMD) Profile
OUR NEW PROFILE IS: (NASDAQ: MYMD) RA AFFECTS UP TO 14 MILLION PEOPLE AROUND THE WORLD MYMD PHARMACEUTICALS PLANS FDA-CLEARED PHASE 2 CLINICAL TRIAL OF MYMD-1 IN RHEUMATOID ARTHRITIS MYMD PHARMACEUTICALS REPORTS STATISTICALLY SIGNIFICANT POSITIVE TOPLINE PHASE 2 RESULTS FOR NEXT GENERATION ORAL TNF-Α INHIBITOR MYMD-1® IN SARCOPENIA/AGE-RELATED FRAILTY VIEW THE INVESTOR PRESENTATION HERE _______________________________ Hello […]
(Nasdaq: BRSH) Profile
OUR NEW PROFILE IS: (NASDAQ: BRSH) BREAKING NEWS ON FRIDAY: BRUUSH ORAL CARE INC. AND ARRIVE TECHNOLOGY INC. ANNOUNCE AGREEMENT AND PLAN OF MERGER BRUUSH IS ENDORSED BY FAMOUS COMEDIAN KEVIN HART THEY HAVE RECEIVED OVER 3,000 ORGANIC REVIEWS WITH A 90% 5-STAR RATING THEIR RETURN RATE IS LESS THAN 1%, COMPARED TO A U.S. NATIONAL […]
(Nasdaq: MGRX) Profile
OUR NEW PROFILE IS: (NASDAQ: MGRX) 52% OF MEN EXPERIENCE SOME FORM OF ERECTILE DYSFUNCTION THROUGHOUT THEIR LIFE AND THAT TOTAL INCREASES ANYWHERE FROM 5-15% BETWEEN AGES 40 AND 70 MANGOCEUTICALS LAUNCHES MANGORX MEXICO SUBSIDIARY, PAVING THE WAY FOR OVER-THE-COUNTER RETAIL OF ERECTILE DYSFUNCTION LINE OF PRODUCTS IN LATIN AMERICA MGRX EXPERIENCED SEQUENTIAL REVENUE GROWTH […]
(Nasdaq: SLNH) Profile
OUR NEW PROFILE IS: (NASDAQ: SLNH) THIS DATA CENTER JUGGERNAUT IS SOLVING RENEWABLE ENERGY’SBIGGEST PROBLEM ALL WHILE BENEFITING FROM THE RISE OF BITCOIN REVENUE IN THE THIRD QUARTER INCREASED BY 176% TO $5.8 MILLION COMPARED TO $2.1 MILLION IN THE SECOND QUARTER OF 2023 SOLUNA HARNESSES THE POWER OF COMPUTING TO ACCELERATE THE RENEWABLE ENERGY FUTURE SLNH COMPLETED […]
(Nasdaq: ANIX) Profile
OUR NEW PROFILE IS: (NASDAQ: ANIX) ANIX HAS TWO VACCINES AIMED TO PREVENT BREAST CANCER AND OVARIAN CANCER ANIX HAD $23 MILLION IN CASH AS OF JULY 2023 CHECK OUT THE INVESTOR PRESENTATION HERE ____________________ Hello Everyone, Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of […]
(Nasdaq: GDC) Profile
OUR NEW PROFILE IS: (NASDAQ: GDC) ____________________ GD CULTURE GROUP EXPANDS INTO LIVESTREAMING INTERACTIVE GAMES ON TIKTOK GDC HAS BEEN SEEING A LOT OF ACTIVITY OVER THE PAST 7 DAYS GD CULTURE GROUP UNVEILS ITS TRANSFORMATIVE AND PHOTOREALISTIC AI-DRIVEN DIGITAL HUMAN TECHNOLOGY ON TIKTOK GD CULTURE GROUP ENTERS INTO MEMORANDUM OF UNDERSTANDING WITH PIER E […]
(NYSE American: MAIA) Profile
OUR NEW PROFILE IS: (NYSE AMERICAN: MAIA) MAIA BIOTECHNOLOGY RECENTLY ANNOUNCES SHARE REPURCHASE PROGRAM MAIA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR THIO, A FIRST-IN-CLASS TELOMERE TARGETING AGENT FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA. -THIS […]